Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients

2018 ◽  
Vol 19 (6) ◽  
pp. 899-905 ◽  
Author(s):  
Macartney Welborn ◽  
Shelby L. Kubicki ◽  
Naveen Garg ◽  
Anisha B. Patel
Keyword(s):  
Adverse Events ◽  
Chart Review ◽  
Retrospective Chart Review

Retrospective Chart Review of Cryopreserved Amniotic Membrane for Knee Pain

2020 ◽  
Author(s):  
Ruben Berrocal Timmons
Keyword(s):  
Quality Of Life ◽  
Adverse Events ◽  
Amniotic Membrane ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Final Analysis ◽  
Mean Values ◽  
Number Of Patients ◽  
The Impact

Objective: Treatment of joint pain with an injection of the amniotic membrane has not been adequately studied. This study retrospectively reviewed Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and analgesic usage data from patients treated with the injection of cryopreserved amniotic membrane (CAM) in their knees to determine the impact of treatment on patients’ pain, quality of life, and analgesic usage. Methods: Chart review was conducted on 40 patients. Institutional Review Board (IRB) approval was obtained prior to initiation of the project. The membrane was utilized as per the FDA guidance of 21CFR1271. Retrospective data, including demographics, medical history, pain score, quality of life score, analgesic usage and adverse events, were collected from their medical records for each consenting patient through 6 months after CAM injection. Results: A total of 40 patients were considered in the final analysis. Mean VAS for pain level improved from 7.0 to 2.6 (p<0.001). WOMAC daily activity function score improved from a mean score of 52 to 28 (p<0.001). Opioid and non-steroidal anti-inflammatory drug (NSAID) usage decreased from 97% to 25% (p<0.001). No adverse events were reported. Conclusion: Mean values for VAS and WOMAC scores significantly improved at all time points and the number of patients who used analgesics decreased as compared to baseline. CAM injection into painful knee joints decreases pain, improves physical function, and decreases the use of analgesics in the absence of adverse events.

scholarly journals Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Tara A. Lindeman ◽  
Joan M. Duggan ◽  
Eric G. Sahloff
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Trials ◽  
Adverse Events ◽  
Serum Creatinine ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Integrase Inhibitor ◽  
Serious Adverse Events ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1

Abstract This retrospective chart review evaluated changes in serum creatinine and creatinine clearance (CrCl) after initiation of an integrase inhibitor (INSTI)-based regimen as initial treatment in human immunodeficiency virus-infected adults. Serum creatinine and CrCl changes were similar to those seen in clinical trials for INSTIs. No renal-related serious adverse events or discontinuations occurred.

Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus

2007 ◽  
Vol 28 (6) ◽  
pp. 695-701 ◽  
Author(s):  
A. Luque ◽  
S. Hulse ◽  
D. Wang ◽  
U. Shahzad ◽  
E. Tanzman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Occupational Exposure ◽  
Adverse Events ◽  
Healthcare Workers ◽  
Health Program ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Preventive Treatment ◽  
Postexposure Prophylaxis ◽  
Immunodeficiency Virus

Objective.To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).Methods.Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.Setting.University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.Participants.Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.Results.We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.Conclusion.Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

Bipolar Radio Frequency as an Adjunct to Face and Body Contouring: A 745-Patient Clinical Experience

2021 ◽  
Author(s):  
Jonathan Cook ◽  
Barry E DiBernardo ◽  
Jason N Pozner
Keyword(s):  
Adverse Events ◽  
Clinical Experience ◽  
Chart Review ◽  
Body Contouring ◽  
Specific Treatment ◽  
Retrospective Chart Review ◽  
The Body ◽  
New Paradigm ◽  
Skin Laxity ◽  
Fat Removal

Abstract Background Radiofrequency (RF) technology has ushered in a new paradigm in body contouring for patients with mild to moderate skin laxity who desire fat removal without exacerbating skin laxity issues. The authors utilized a bipolar internal RF device as an adjunct to liposuction and found the device to simpler and more accurate than previous technologies. Objectives Our study aims to review our clinical experience with bipolar RF assisted liposuction (RFAL). Methods A review of our large experience with bipolar RFAL was completed, with evaluation of the nuances from appropriate patient selection and specific treatment areas. The authors treated 745 patients from January 2017 to January 2020 at two centers. A retrospective chart review was performed of the first and last 50 patients treated at each center (for a total of 100 patients in each group), to assess trends in outcomes and adverse events. Results Results were generally excellent from physician evaluation, and overall patient satisfaction was high (96%). The two most common adverse events were temporary swelling (9%) and nodules (8.5%). Selected examples of a variety of cases are reviewed. Conclusions The ability to tighten skin with a minimally invasive tool adds much to the contemporary approach to the body contouring patient with skin laxity. Adverse events were minimal and greatly decreased after an initial short learning curve. Bipolar RFAL is a strong addition to our surgical armamentarium and has become one of the essential tools for our practices.

scholarly journals Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia

2021 ◽  
Author(s):  
Jing-Zhou Hou ◽  
Kellie Ryan ◽  
Senxi Du ◽  
Bruno Fang ◽  
Stanley Marks ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Adverse Events ◽  
Dose Reduction ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
First Line ◽  
Dose Reductions

Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). Conclusion: Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.

scholarly journals Use of a Silicon Stoma Stent as an Interim Step in High-Risk Tracheostomy Decannulation

OTO Open ◽  
2019 ◽  
Vol 3 (1) ◽  
pp. 2473974X1983643
Author(s):  
Jacqueline Ross ◽  
Kristy McMurray ◽  
Tanis Cameron ◽  
Celia Lanteri
Keyword(s):  
High Risk ◽  
Adverse Events ◽  
Chart Review ◽  
Care Service ◽  
Health Care Service ◽  
Retrospective Chart Review ◽  
Airway Patency ◽  
Morbidity Burden ◽  
Airway Access ◽  
Reasons For Use

Objective To describe use of a stoma stent to facilitate high-risk decannulation. Methods Retrospective chart review of 14 consecutive patients who received a stent from March 2013 to December 2016 at a quaternary health care service. Primary outcome measures were decannulation outcome and adverse events. Results Decannulation outcome: 12 of 14 patients had their tracheostomy tube (TT) removal facilitated by stent use. Patients had the stent for a median of 6 days (interquartile range, 49). Reasons for use included medical instability, risk of sputum retention, uncertain airway patency, and the need for ongoing airway access. All patients survived to discharge. One patient residing in the community has retained a stoma stent. Adverse events: One patient removed the stent on the day of insertion, necessitating reinsertion of the TT. Granulation tissue at the stoma site was seen in 2 patients. Discussion A tracheostoma will normally close within 48 hours following decannulation, which is problematic if TT reinsertion is required. By using the stent, reversal of decannulation becomes a simple ward-based procedure. In comparison to a TT, which is secured with ties, the stoma stent proved unsuitable for use in an agitated patient. Implications for Practice Decreasing total cannulation time is of benefit as patients with tracheostomy are subject to high rates of complications and adverse events. A stoma stent poses little risk and a low morbidity burden to the patient in comparison to alternative management.

scholarly journals P081: Combative patients given prehospital midazolam as a chemical restraint: adverse events and efficacy in the emergency department

CJEM ◽  
2017 ◽  
Vol 19 (S1) ◽  
pp. S105
Author(s):  
M. Davis ◽  
L. Leggatt ◽  
K. Van Aarsen ◽  
P. Bradford ◽  
P. Morassutti ◽  
...  
Keyword(s):  
Emergency Department ◽  
Adverse Events ◽  
Chart Review ◽  
A Priori ◽  
Retrospective Chart Review ◽  
Prehospital Setting ◽  
Urban Centers ◽  
Chemical Restraint ◽  
Underlying Pathology ◽  
Do So

Introduction: Paramedics are required to manage combative patients. In order to do so safely, chemical sedation may be required. Advanced Care Paramedics in our EMS system utilize midazolam for chemical restraint. Our previous research has shown that midazolam appears to have few prehospital adverse events (AEs) associated with its use. However, it required multiple dosages in 33.3% of patients and was deemed ineffective in 15.1% of patients that received it in the prehospital setting. Objective: To determine Emergency Department (ED) AEs associated with the prehospital use of midazolam in combative patients and determine the efficacy of this agent as a chemical restraint during the first hour of the ED stay. Methods: A retrospective chart review of paramedic calls from 2 urban centers, from January 2012 to December 2015 was completed. All cases of combative patients were examined. Patients were excluded if they were 17 or younger. Ambulance call records were linked to the patient’s ED chart. ED charts were reviewed and a priori endpoints were extracted. Results: Of approximately 350,000 calls, there were 269 patients that were combative. Of these, 186 (69.1%) received midazolam in the prehospital setting. During the first hour of their ED stay, 68 (36.5%) required further sedation, while 118 (63.4%) patients did not. Of the 186 patients who received midazolam in the prehospital setting there was one death and one AE in the ED (defined as hypotension, bradypnea, or need for airway intervention). After further review of the charts, both AEs were deemed likely resulting from underlying pathology and not related to the use of midazolam. The average ED Length of stay (LOS) was 7.6 hours for all patients. A total of 82 (44.1%) were admitted to hospital with a mean in hospital LOS of 13.1 days. Conclusion: Prehospital use of midazolam for combative patients appears to be safe, with no reported delayed AEs. 36.5% of this cohort required further sedation within 1 hour of their ED arrival. This supports previous findings that midazolam was ineffective in 15.1 % of prehospital combative patients. Further study is required to determine midazolam’s efficacy and AE profile compared to other prehospital agents in order to ensure optimal safety of both patients and paramedics.

Sign in / Sign up

Export Citation Format

Share Document